REMINDER: Our webinar on “Fighting Counterfeits with

New Post Public Reply Private Reply Replies (0) Message Board
solartech
329
REMINDER: Our webinar on “Fighting Counterfeits with Quantum Dots and Blockchain” is just one week away. Thanks to all that have registered. If you haven't yet registered, please be sure to sign up today. All the details are below.

Since Quantum Materials announced its anti-counterfeit focus a month back, we've been inundated with interest in our quantum dot/blockchain approach to addressing this global criminal enterprise.

As one way to respond to this interest, which is incredibly motivating for us, we plan to host an educational webinar to explain more about our vision in the anti-counterfeit space, our technology response and the use cases and overall market opportunity.

The webinar will take place on Tuesday, November 19 at 10am US central time. Anyone can tune in, from anywhere in the world. But you need to register beforehand. Register for the webinar using the button below.

We're looking forward to this webinar, which we expect to be the first episode of a regular channel to keep our investors, partners and customers updated on all the exciting developments happening here at Quantum Materials.

Best,

Stephen B. Squires
President & CEO
Quantum Materials Corp.

Participants from Quantum Materials will be:

- Stephen B. Squires, President & CEO, who will cover company vision.
- Jay M Williams, Chief Technology Officer, who will provide information on the combination of quantum dots and blockchain.
- John T. Hartigan, Chief Revenue Officer, who will offer insight into use cases and the market opportunity.

The participants will make short presentations and answer your questions.

We look forward to your attendance as we outline this exciting new business opportunity for quantum dots.

Or iPhone one-tap :
US: +17207072699,,463555459# or +16465588656,,463555459#

Or Telephone:
Dial(for higher quality, dial a number based on your current location):
US: +1 720 707 2699 or +1 646 558 8656
Canada: +1 647 558 0588
Italy: +39 069 480 6488 or +39 020 066 7245
France: +33 7 5678 4048 or +33 170 37 2246 or +33 1 7037 9729
Australia: +61 8 7150 1149 or +61 2 8015 6011
Germany: +49 69 7104 9922 or +49 30 3080 6188 or +49 30 5679 5800
Singapore: +65 3165 1065 or +65 3158 7288
Spain: +34 917 873 431 or +34 84 368 5025
Switzerland: +41 43 210 70 42 or +41 22 518 89 78 or +41 31 528 09 88
United Kingdom: +44 203 051 2874 or +44 203 481 5237 or +44 203 966 3809 or +44 131 460 1196
Webinar ID: 463 555 459
International numbers available: https://zoom.us/u/acqXttKaoh


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Breakout has occured as investors anticipate the Webinar on Tuesday November 19.

http://bigcharts.marketwatch.com/advchart/fra...33&y=5

I think QMC will has at least 10 quantum dot continuous flow production IP licensees from at least 10 countries taking the opportunity of selling quantum dots to brand name manufacturers in their own country to fight counterfeiting, to protect the reputation of their brand name and to capture market share from the counterfeiters.

10 x $1 million licensing fee = $10 million
10 x $1 million micro reactor sales = $10 million
10 x ? million annual royalties =

Estimate for licensees' annual quantum dot sales:

For example, for annual sales of each one tonne (1 million grams) at US$50 per gram, each licensee's annual sales will be US$50 million
5% royalties = $2.5 million
Total annual royalties from just 10 licensees: $25 million
QMC's current Annual Operating cost: $7 million
QMC's Net Earnings: $18 million
QTMM Current S/O: 631 million
Net Earnings per share: $0.03
P/E ratio: 72 (assume to be the same as UDC's)
Projected share price: $2.16
Projected market capitalization: $1.36 billion

Those interested in attending the Webinar should visit QMC's website and fill in the registration form.

https://www.quantummaterialscorp.com/
























Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading